Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randy Yeh

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
Clinical Nuclear Medicine|February 29, 2020
FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With PembrolizumabRandy Yeh, Megan H Trager, Emanuelle M Rizk, et al.
Oncoimmunology|May 10, 2019
Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapyRomain-David Seban, Charlotte Robert, Laurent Dercle, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 9, 2025
Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy AnalysisRandy Yeh, Fresia Pareja, Parnian Shobeiri, et al.
Clinical Imaging|July 31, 2025
The evolving role of multimodal imaging, artificial intelligence and radiomics in the radiologic assessment of immune related adverse eventsJeeban P Das, Hong Y Ma, Dorine de Jong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2022
Initial Results of <sup>68</sup>Ga-FAPI-46 PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast CancerPhilipp Backhaus, Matthias C Burg, Inga Asmus, et al.
Insights Into Imaging|February 9, 2026
Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided managementAurelie Choucair, Anna Zdunek, Matthew Liao, et al.
Radiology|June 10, 2020
Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted <sup>89</sup>Zr-Pertuzumab PET/CTGary A Ulaner, Jorge A Carrasquillo, Christopher C Riedl, et al.
Diagnostics (Basel, Switzerland)|May 28, 2022
Translating Molecules into Imaging-The Development of New PET Tracers for Patients with MelanomaLaetitia Vercellino, Dorine de Jong, Laurent Dercle, et al.
Journal of Vascular and Interventional Radiology : JVIR|January 12, 2024
Three-Dimensional Margin as a Predictor of Local Tumor Progression after Microwave Ablation: Intraprocedural versus 4-8-Week Postablation AssessmentMahdi Zirakchian Zadeh, Vlasios S Sotirchos, Assen Kirov, et al.
Cancers|December 23, 2022
Real-Time Split-Dose PET/CT-Guided Ablation Improves Colorectal Liver Metastasis Detection and Ablation Zone Margin Assessments without the Need for Repeated Contrast InjectionMahdi Zirakchian Zadeh, Randy Yeh, Henry S Kunin, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Clinical Nuclear Medicine|February 29, 2020
FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With PembrolizumabRandy Yeh, Megan H Trager, Emanuelle M Rizk, et al.
Oncoimmunology|May 10, 2019
Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapyRomain-David Seban, Charlotte Robert, Laurent Dercle, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 9, 2025
Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy AnalysisRandy Yeh, Fresia Pareja, Parnian Shobeiri, et al.
Clinical Imaging|July 31, 2025
The evolving role of multimodal imaging, artificial intelligence and radiomics in the radiologic assessment of immune related adverse eventsJeeban P Das, Hong Y Ma, Dorine de Jong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2022
Initial Results of <sup>68</sup>Ga-FAPI-46 PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast CancerPhilipp Backhaus, Matthias C Burg, Inga Asmus, et al.
Insights Into Imaging|February 9, 2026
Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided managementAurelie Choucair, Anna Zdunek, Matthew Liao, et al.
Radiology|June 10, 2020
Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted <sup>89</sup>Zr-Pertuzumab PET/CTGary A Ulaner, Jorge A Carrasquillo, Christopher C Riedl, et al.
Diagnostics (Basel, Switzerland)|May 28, 2022
Translating Molecules into Imaging-The Development of New PET Tracers for Patients with MelanomaLaetitia Vercellino, Dorine de Jong, Laurent Dercle, et al.
Journal of Vascular and Interventional Radiology : JVIR|January 12, 2024
Three-Dimensional Margin as a Predictor of Local Tumor Progression after Microwave Ablation: Intraprocedural versus 4-8-Week Postablation AssessmentMahdi Zirakchian Zadeh, Vlasios S Sotirchos, Assen Kirov, et al.
Cancers|December 23, 2022
Real-Time Split-Dose PET/CT-Guided Ablation Improves Colorectal Liver Metastasis Detection and Ablation Zone Margin Assessments without the Need for Repeated Contrast InjectionMahdi Zirakchian Zadeh, Randy Yeh, Henry S Kunin, et al.
Pageof 8